J Watanabe1,2, M Saito3, Y Horimoto3, S Nakamoto4. 1. Division of Breast Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shizuoka, Japan. j.watanabe@scchr.jp. 2. Division of Breast Oncology, Juntendo University Hospital, Tokyo, Japan. j.watanabe@scchr.jp. 3. Division of Breast Oncology, Juntendo University Hospital, Tokyo, Japan. 4. Division of Breast Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shizuoka, Japan.
Abstract
PURPOSE: Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. Recently, a maintained baseline lymphocyte count was proposed as predictive marker for eribulin therapy in HER2-ABC patients; however, no associations with the OS have been noted. We retrospectively investigated the neutrophil-to-lymphocyte ratio and absolute lymphocyte count (ALC) in HER2-ABC patients receiving eribulin and assessed the utility of eribulin re-administration for further OS improvement. METHODS: HER2-ABC patients who received eribulin therapy at Shizuoka Cancer Center between November 2011 and December 2018 were retrospectively analyzed. RESULTS: A total of 144 HER2-ABC (108 estrogen receptor-positive [ER+], 36 ER-) patients were identified, and 32 patients (28 ER+ , 4 ER-) were re-administered with eribulin. In the ER+ subgroup, a multivariate analysis showed that an ALC ≥ 1000/μL and re-administration were significantly associated with the OS (hazard ratio [HR] 0.503; P = 0.034 and HR 0.366; P < 0.0001, respectively), and an ALC ≥ 1000/μL was also identified as the only predictive factor for re-administration (HR 0.329; P = 0.033). In contrast, a multivariate analysis in the ER- subgroup identified no predictive markers. CONCLUSION: In HER2-ER + ABC patients, ALC was identified as a predictive marker for eribulin therapy, and the re-administration of eribulin is considered a valid therapeutic option for further improvement of the OS.
PURPOSE: Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. Recently, a maintained baseline lymphocyte count was proposed as predictive marker for eribulin therapy in HER2-ABCpatients; however, no associations with the OS have been noted. We retrospectively investigated the neutrophil-to-lymphocyte ratio and absolute lymphocyte count (ALC) in HER2-ABCpatients receiving eribulin and assessed the utility of eribulin re-administration for further OS improvement. METHODS:HER2-ABCpatients who received eribulin therapy at Shizuoka Cancer Center between November 2011 and December 2018 were retrospectively analyzed. RESULTS: A total of 144 HER2-ABC (108 estrogen receptor-positive [ER+], 36 ER-) patients were identified, and 32 patients (28 ER+ , 4 ER-) were re-administered with eribulin. In the ER+ subgroup, a multivariate analysis showed that an ALC ≥ 1000/μL and re-administration were significantly associated with the OS (hazard ratio [HR] 0.503; P = 0.034 and HR 0.366; P < 0.0001, respectively), and an ALC ≥ 1000/μL was also identified as the only predictive factor for re-administration (HR 0.329; P = 0.033). In contrast, a multivariate analysis in the ER- subgroup identified no predictive markers. CONCLUSION: In HER2-ER + ABCpatients, ALC was identified as a predictive marker for eribulin therapy, and the re-administration of eribulin is considered a valid therapeutic option for further improvement of the OS.
Authors: Javier Cortes; Linda Vahdat; Joanne L Blum; Chris Twelves; Mario Campone; Henri Roché; Thomas Bachelot; Ahmad Awada; Robert Paridaens; Anthony Goncalves; Dale E Shuster; Jantien Wanders; Fang Fang; Renuka Gurnani; Elaine Richmond; Patricia E Cole; Simon Ashworth; Mary Ann Allison Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Peter A Kaufman; Ahmad Awada; Chris Twelves; Louise Yelle; Edith A Perez; Galina Velikova; Martin S Olivo; Yi He; Corina E Dutcus; Javier Cortes Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: T Yoshida; Y Ozawa; T Kimura; Y Sato; G Kuznetsov; S Xu; M Uesugi; S Agoulnik; N Taylor; Y Funahashi; J Matsui Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640
Authors: Chris Twelves; Javier Cortes; Linda Vahdat; Martin Olivo; Yi He; Peter A Kaufman; Ahmad Awada Journal: Breast Cancer Res Treat Date: 2014-11-08 Impact factor: 4.872
Authors: F Cardoso; A Costa; E Senkus; M Aapro; F André; C H Barrios; J Bergh; G Bhattacharyya; L Biganzoli; M J Cardoso; L Carey; D Corneliussen-James; G Curigliano; V Dieras; N El Saghir; A Eniu; L Fallowfield; D Fenech; P Francis; K Gelmon; A Gennari; N Harbeck; C Hudis; B Kaufman; I Krop; M Mayer; H Meijer; S Mertz; S Ohno; O Pagani; E Papadopoulos; F Peccatori; F Penault-Llorca; M J Piccart; J Y Pierga; H Rugo; L Shockney; G Sledge; S Swain; C Thomssen; A Tutt; D Vorobiof; B Xu; L Norton; E Winer Journal: Ann Oncol Date: 2017-01-01 Impact factor: 32.976